Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
NCT05995405 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.
Conditions Studied
Interventions
- DRUG GTX-104
- DRUG Nimotop 30 MG Oral Capsule
Study Locations (20)
Ohio
- University of Cincinnati Medical Center — Cincinnati
- University Hospitals Cleveland Medical Center — Cleveland
- The Ohio State University Wexner Medical Center — Columbus
North Carolina
- University of North Carolina — Chapel Hill
- Duke University — Durham
Tennessee
- Methodist University Hospital — Memphis
- Vanderbilt University Medical Center — Nashville
Alabama
- The University of Alabama at Birmingham — Birmingham
Arizona
- Brain and Spine Neurological Institute — Phoenix
California
- Community Regional Medical Center — Fresno
Florida
- Mayo Clinic Florida — Jacksonville
Georgia
- Emory University School of Medicine Emergency Neurosciences — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2024-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05995405
The ClinicalTrials.gov registry entry for NCT05995405 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grace Therapeutics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Aneurysmal Subarachnoid Hemorrhage (aSAH) appearing as the primary indexed condition, and to 2 interventions — of which GTX-104 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05995405 reports 20 study locations spanning 16 distinct geographic areas — top geographies include Ohio, North Carolina, Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05995405 about?
NCT05995405 is a clinical study titled "Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH". The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.
What is the current status of trial NCT05995405?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2023-10-20. Estimated completion is 2024-12.
What conditions does trial NCT05995405 study?
This clinical trial studies the following conditions: Aneurysmal Subarachnoid Hemorrhage (aSAH). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05995405?
The interventions under investigation include: GTX-104 (DRUG), Nimotop 30 MG Oral Capsule (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05995405?
This trial is sponsored by Grace Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05995405 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.